Assessment of the quality, diagnosis, and therapeutic recommendations of clinical practice guidelines on patients with Helicobacter pylori infection : A systematic review
Copyright © 2024 Elsevier España, S.L.U. All rights reserved..
We conducted this study to systematically review and assess the current clinical practice guidelines (CPGs) related to the diagnosis and treatment of Helicobacter pylori (H. pylori) infection. The aim was to evaluate the quality of these included CPGs and provide clinicians with a convenient and comprehensive reference for updating their own CPGs. We searched four databases to identify eligible CPGs focusing on H. pylori diagnosis and treatment recommendations. The results were presented using evidence mappings. Quality and clinical applicability were assessed comprehensively using AGREE-II and AGREE-REX. Statistical tests, specifically Bonferroni tests, were employed to compare the quality between evidence-based guidelines and consensus. A total of 30 eligible CPGs were included, comprising 17 consensuses and 13 guidelines. The quality showed no statistical significance between consensuses and guidelines, mainly within the moderate to low range. Notably, recommendations across CPGs exhibited inconsistency. Nevertheless, concerning diagnosis, the urea breath test emerged as the most frequently recommended method for testing H. pylori. Regarding treatment, bismuth quadruple therapy stood out as the predominantly recommended eradication strategy, with high-dose dual therapy being a newly recommended option. Our findings suggest the need for specific organizations to update their CPGs on H. pylori or refer to recently published CPGs. Specifically, CPGs for pediatric cases require improvement and updating, while a notable absence of CPGs for the elderly was observed. Furthermore, there is a pressing need to improve the overall quality of CPGs related to H. pylori. Regarding recommendations, additional evidence is essential to elucidate the relationship between H. pylori infection and other diseases and refine test indications. Clinicians are encouraged to consider bismuth quadruple or high-dose dual therapy, incorporating locally sensitive antibiotics, as empirical radical therapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Gastroenterologia y hepatologia - (2024) vom: 01. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Muyang [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 22.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.gastrohep.2024.01.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367968673 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367968673 | ||
| 003 | DE-627 | ||
| 005 | 20240229144302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240203s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.gastrohep.2024.01.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM367968673 | ||
| 035 | |a (NLM)38307489 | ||
| 035 | |a (PII)S0210-5705(24)00024-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Muyang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of the quality, diagnosis, and therapeutic recommendations of clinical practice guidelines on patients with Helicobacter pylori infection |b A systematic review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a We conducted this study to systematically review and assess the current clinical practice guidelines (CPGs) related to the diagnosis and treatment of Helicobacter pylori (H. pylori) infection. The aim was to evaluate the quality of these included CPGs and provide clinicians with a convenient and comprehensive reference for updating their own CPGs. We searched four databases to identify eligible CPGs focusing on H. pylori diagnosis and treatment recommendations. The results were presented using evidence mappings. Quality and clinical applicability were assessed comprehensively using AGREE-II and AGREE-REX. Statistical tests, specifically Bonferroni tests, were employed to compare the quality between evidence-based guidelines and consensus. A total of 30 eligible CPGs were included, comprising 17 consensuses and 13 guidelines. The quality showed no statistical significance between consensuses and guidelines, mainly within the moderate to low range. Notably, recommendations across CPGs exhibited inconsistency. Nevertheless, concerning diagnosis, the urea breath test emerged as the most frequently recommended method for testing H. pylori. Regarding treatment, bismuth quadruple therapy stood out as the predominantly recommended eradication strategy, with high-dose dual therapy being a newly recommended option. Our findings suggest the need for specific organizations to update their CPGs on H. pylori or refer to recently published CPGs. Specifically, CPGs for pediatric cases require improvement and updating, while a notable absence of CPGs for the elderly was observed. Furthermore, there is a pressing need to improve the overall quality of CPGs related to H. pylori. Regarding recommendations, additional evidence is essential to elucidate the relationship between H. pylori infection and other diseases and refine test indications. Clinicians are encouraged to consider bismuth quadruple or high-dose dual therapy, incorporating locally sensitive antibiotics, as empirical radical therapy. | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Clinical practice guidelines | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Diagnóstico | |
| 650 | 4 | |a Estrategias terapéuticas | |
| 650 | 4 | |a Evaluación de la calidad | |
| 650 | 4 | |a Evidence mapping | |
| 650 | 4 | |a Guías de práctica clínica | |
| 650 | 4 | |a Helicobacter pylori | |
| 650 | 4 | |a Mapeo de la evidencia | |
| 650 | 4 | |a Quality evaluation | |
| 650 | 4 | |a Therapeutic strategies | |
| 700 | 1 | |a Ma, Xueni |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Huimei |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Mengyu |e verfasserin |4 aut | |
| 700 | 1 | |a Gou, Lingzhu |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Hongwei |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Lina |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Dekui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastroenterologia y hepatologia |d 1993 |g (2024) vom: 01. Feb. |w (DE-627)NLM075187280 |x 0210-5705 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:01 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gastrohep.2024.01.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 01 |c 02 | ||